INTRODUCTION
Human nocardioses are caused by members of the Nocardia species. Coupled with the increasing number of the immunocompromised patients who are treated with steroids or broad-spectrum antibiotics, and of AIDS and organ transplant patients, the incidence of infection is increasing [1] [2] [3] . Concomitant with introduction of new genetic technologies for Nocardia classification, reports of new species of Nocardia have increased: during 2004 2007, more than 40 species were established 4) . Our recent phylogenetic studies of these clinical Nocardia isolates have suggested the presence of many new species among the isolated strains. Detailed taxonomic studies have identified more than 17 new Nocardia species 5) . Nocardia species show species-specific drug susceptibility patterns; consequently, development of simpler and more rapid identification methods is expected because identification is necessary to initiate proper antibiotic therapy. In 2004, whole-genome analysis of N. farcinica was completed; that information was publicized 6) . That genomic information engendered discovery of new secondary metabolites such as siderophore compounds, which have been considered to be related to virulence factors in pathogenic bacteria.
New sources of bioactive materials such as marine organisms and new microbes from different ecological niches have promoted recent advances in the discovery of new drugs. However, such attention has never been paid to pathogenic microbes such as pathogenic Nocardia. We continue our interest in biologically active compounds from pathogenic microorganisms, especially from pathogenic microorganisms because: i) pathogenic microorganisms should have unique competition mechanisms between pathogenic microbes and other microbes, plants, and animals; ii) pathogenic microbes have never been considered to be new sources of biologically active metabolites; and iii) pathogenic microbes should be biologically more active and have different metabolic pathways than those of nonpathogenic microbes. Furthermore, 60-100 strains of pathogenic Nocardia have been referred to our research center every year for identification from clinical laboratories in Japan, and the numbers of the maintained cultures are increasing 7) . These facts have stimulated our screening studies of secondary active metabolites from these pathogenic Nocardia 8) .
Nocardia is an aerobic Gram-positive, filamentous and partially acid-fast bacterium, which is classified among the pathogenic actinomycetes. Among the Nocardia species, N. asteroides complex (N. asteroides sensu strict, N. farcinica and N. nova), N. brasiliensis, N. otitidiscaviarum, N. transvalensis, N. cyriacigeorgica, N. asiatica, and N. beijingensis cause human infections. Reportedly, infection caused by Nocardia is uncommon, and has been considered to be rare 8, 9) . However, coupled with the increasing number of the immunocompromised patients treated with steroids, AIDS, and organ transplant patients, the frequency of cases of nocardiosis is increasing in Japan.
Taxonomic studies of these Nocardia clinical isolates revealed more than 17 new Nocardia species and three new species of Gordonia strains. Nocardia is known to have species-specific drug-resistance patterns, and we had reported various novel resistance mechanisms, including glucosylation, phosphorylation, and ribosylation of rifampicin. This constitutes the first report of ribosylation as an antibiotic resistance mechanism.
During the course of our screening program for new bioactive metabolites including immunosuppressive, antifungal, and other bioactive compounds, those compounds were isolated and their structures and biological activities were determined. Our studies of biologically active metabolites using clinical isolates of Nocardia species revealed more than 20 new bioactive compounds with unique structures and biological activities.
PROPOSAL OF NEW SPECIES OF NOCARDIA ISOLATED FROM CLINICAL SAMPLES IN JAPAN
In 2004, we proposed one new species of Nocardia: N. asiatica 10) . Thereafter, we proposed more than 16 new species of Nocardia ( Fig. 1) : N. anaemiae, N. aobensis, N. araoensis, N. arthritidis, N. concave, N. exalbida, N. higoensis, N. inohanensis, N. niigatensis, N. pneumoniae, N. shimofusensis, N. sienata, N. testacea, N. thailandica, N. vermuculata, and N. yamanashiensis [11] [12] [13] [14] . Recently, we also proposed one new species of Nocardia: N. terpenica 5) . In addition to a new species of Nocardia, we also proposed three new species of Gordonia which were isolated from Japanese patients: G. araii, G. effuse and G. otitidis Rifampicin is a valuable chemotherapeutic agent that is used to combat infections such as tuberculosis, staphylococcal infections, and some infections caused by Gram-negative organisms 17, 18) . After the introduction of rifampicin to clinical practice in 1972, resistant strains came to be identified 19) . Classically, microbes resist the action of antibiotics by target-site alteration. This was true in rifampicin in M. tuberculosis 20) . Another way in which bacteria might respond to antibiotic challenge occurs by inactivation of the drug 21) . We had reported three new inactivation mechanisms: decomposition, glucosylation, and phosphorylation (Fig. 2) in pathogenic actinomycetes [22] [23] [24] . In addition, ribosylation has been identified for some fast-growing Mycobacterium species: M. smegmatis, M. avium, and M. parafortuitum. The DNA from M. smegmatis DSM 43756 responsible for this phenotype was cloned and characterized. Biochemical studies showed that the gene encoded a mono-ADP-ribosyltransferase; it was therefore designated as adr for ADP-ribosylation of rifampicin (Fig. 3 ) 25) . The enzyme consists of 143 amino acids and has a molecular weight of 15.9 kDa. In vitro experiments revealed that NAD is the preferred cofactor for inactivation. During our characterization of IN53, a class-1 plasmid-located and composite transposonlocated integron of Escherichia coli which carries an unusual array of gene cassettes, this bacterium was found to have a gene that is responsible for rifampicin inactivation 19) .
BIOACTIVE SECONDARY METABOLITES FROM PATHOGENIC NOCARDIA
Our continuing studies of bioactive metabolites from pathogenic Nocardia have revealed new bioactive metabolites from Nocardia clinical isolates; we found that most N. brasiliensis strains produce antibacterial compounds against Gram-positive bacteria. The 13 strains were found to produce antimicrobial compounds when 22 strains of N. brasiliensis were selected randomly and their antimicrobial activities were tested 26) . Our chemical studies of the antimicrobial compounds showed that, of 11 strains, 9 strains produce a new indole alkaloid named brasilidine A. The remaining strains produced a chelating compound: N,N 0 -ethylenediaminedisuccinic acid (EDDS). Although EDDS itself was already reported to be a microbial product with phospholipase C inhibitory activity, we were able to demonstrate its antimicrobial activity against bacteria and fungi such as Bacillus subtilis and Cryptococcus neoformans. Brasilidine A is a unique compound which possesses a triene unit conjugated with an isonitrile group 27) . In addition to antimicrobial activity, brasilidine A showed antifungal activity against Aspergillus niger 28) . These studies suggested that clinical isolates of N. brasiliensis strains and that other Nocardia strains are useful sources for the screening of bioactive compounds. N. brasiliensis IFM 0089 produced new cytotoxic antibiotics named brasiliquinones A, B and C 29) . Brasiliquinones are unique benz[a]anthraquinone antibiotics with an ethyl group at the C-3 position 29) . Three new compounds, nocarasins A, B and C, were isolated from N. brasiliensis IFM 0677 30) . Nocaracins are new benzenoid metabolites with a geranyl side chain. Nocaracins showed inhibitory activity against some Gram-positive bacteria, especially acid-fast bacteria such as N. asteroides and Mycobacterium smegmatis 30) . Brasilinolides are new 32-membered macrolides with a tetrahydropyrane ring and a 2-deoxypyranose moiety from the broth of N. brasiliensis IFM 0406 31) . Brasilinolides exhibit potent immunosuppressive activity in mouse mixed-lymphocyte assay and antifungal activity against Aspergillus niger (Fig. 4) 
31)
. A novel tricyclic metabolite with potent immunosuppressive activity, brasilicardin A (Fig. 5) , was isolated from the culture broth of the actinomycetes N. brasiliensis IFM 0406 32) . Brasilicardin A is the first tricyclic compound consisting of a perhydrophenanthrene skeleton with a rhamnose, an N-acetylglucosamine, and an amino acid moiety 32) . Brasilicardin A exhibited a potent immunosuppressive activity in mouse mixed-lymphocyte assay. A new antitumor substance was found to be produced by N. asteroides IFM 0959. The compound structure was determined and named asterobactin because of the siderophore nature of the compound 33) . A novel antifungal antibiotic transvalencin A (Fig. 6) 34) , and transvalencin Z 35) were also isolated from a clinical isolate of N. transvalensis IFM 10065, which had been isolated from a patient with actinomycotic mycetoma in Japan. Results of our recent studies suggest that Nocardia strains produce many different type siderophore compounds with different biological activities. Since the discovery of erythromycin A, more than 25 biosynthetic representatives of this family of 14-membered macrolide antibiotics have been reported. Most erythromycins are produced by the genera of Saccharopolyspora and Streptomyces, The strain N. brasiliensis IFM 0466, an isolate from a nocardiosis patient, was found to be an erythromycin E producer 36) . We believe that this is the first isolation report of erythryomycins from N. brasiliensis. Nargenicins were also isolated from N. otitidiscaviarum IFM 0986; to our knowledge, this is also the first isolation of this antibiotic from pathogenic Nocardia. 
